Company

Dr. Betty Clement, an educator, educational consultant and communication arts specialist, is an Adjunct Professor at the University of San Diego, teaching communications and organizational behavior; she also teaches in the Communication Arts Department at Southwestern College and is a consultant to the San Diego Council on Literacy network. She received a Ed.D. from University of Northern Colorado, an M.A. in Administration from University of Northern Colorado and a B.A. from California State University, Sacramento.

​

A. Stephen Dahms, Ph.D., Director of CSUPERB, Professor of Chemistry at Molecular Biology Institute of San Diego State University, Chairman of the Board of Directors of the US Council of Biotecnology Centers, Member of the Advisory Board of Fondazione Cariplo's venture capital arm TT-Ventures. Dr. Dahms was a National Science Foundation and Atomic Energy Commission Postdoctoral Research Fellow; Assistant & Associate & Professor of Chemistry, San Diego State University; Founding Director, Molecular Biology Institute, San Diego State University, Visiting Professor & Alexander von Humboldt Fellow, Institute for Physical Biochemistry, University of Munich; Director California State University Program for Education and Research in Biotechnology. He is Acting Director of the Center for Bio/Pharmaceutical and Biodevice Development, Chairman of the Board of Directors of the Council of Biotechnology Centers/CBC, Member of the BIO Emerging Company Section Governing Body, Member of the Board of Directors of BIOCOM San Diego and Southern California Biomedical Council. He received a B.S. in Chemistry from St. Thomas College, St. Paul and a Ph.D. in Biochemistry from Michigan State University.

​

Shirley A. Jacobs, Founder & CEO Design Perspective Inc., San Diego, and Founder of Spencley & Jacobs Graphics, San Diego, Ms. Jacobs is the recipient of an Award of Excellence from the International Association of Business Communicators; San Diego Press Club and PRSA Awards; Merit Award from the Public Relations Club of San Diego. She received her B.A. from Penn State University.

​

Dr. G. Kenneth Lloyd is also a Director of the Company. Dr. Lloyd is currently Chief Sientific Officer at Beyond Spring Pharmaceutical. Previously he as Chief Scientific Officer, Senior VP Research & Development, Nereus Pharmaceuticals Inc. and has previously held positions as Vice President, Biology & Corporate Officer, SIBIA Neurosciences Inc, La Jolla, CA; Assistant Vice-President & Director of Research, Wyeth-Ayerst Research, Wyeth laboratories (UK), Ltd., Taplow, England; Associate Director, Biology, Synthélabo Recherche, Paris, France; Acting Head, Department of Psychopharmacology, Clarke Institute of Psychiatry, University of Toronto, Toronto, Canada; Assistant Professor, Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, Canada. He is a member of the Board of Directors of Lazarus Pharmaceuticals Inc. and The Scientific Advisory Board of Neuraltus Pharmaceuticals Inc. and was previously a member of The Scientific Advisory Board of The Huntington's Chorea Society of Canada. He has overseen the successful drug discovery and development of several CNS and oncology compounds and has published over 300 scientific articles, edited 5 symposia volumes and sat on many scientific review panels. He has had a career long interest and commitment to Parkinson’s and related diseases research, which commenced during his graduate training. He completed his B.Sc. and M.Sc. (Biochemistry) degrees at McGill University in Montreal with Dr. T.L. Sourkes and his Ph.D. (Pharmacology), with Dr. Oleh Horneykiewicz at the University of Toronto.

​

Dr. Mitchell Malachowski is Professor of Chemistry at the University of San Diego; He was Associate Dean of Arts and Sciences at USD from 1989 to 1994. After teaching at Gettysburg College for one year, he joined the faculty at USD in 1984. During 1992 he was a visiting professor at Leiden University, the Netherlands. He has received several awards for teaching excellence from the University of North Carolina, the administrator of the year award at U.S.D., a University Professorship from U.S.D. (1996-1997) and the Charles B. Willard award for distinguished career achievement from Rhode Island College. He maintains an active research program involving the bioinorganic chemistry of copper and manganese proteins and has received funding from the Petroleum Research Fund, the Research Corporation and Project SEED grants. He received a B.A. degree in Chemistry from Rhode Island College in 1977 and a Ph.D. in Organic Chemistry.

​

Dr. Tom Morris is a Professor of International Business, School of Business, University of San Diego, California. Previously he was a Process Development Engineer, Fairchild Semiconductor, Palo Alto, California; Production Manager, Beckman Instruments Inc., Palo Alto, California; Vice President, Operations, Granville - Phillips Co., Boulder, Colorado; Vice President, - Operations Medtronic IMC Inc., Denver, Colorado; Director of International Operations, COBE Laboratories Inc, Denver, Colorado & Director COBE S.A. Paris, France; Principal International Management Consultants, Boulder, Colorado; Adjunct Professor, University of Denver School of Business, Denver, Colorado. He received a B.S. in Industrial Engineering from University of Minnesota, a B.S. in Business Finance from University of Colorado, an M.B.A. in Management from University of Denver and a Ph.D. in International Business from University of Denver.

​

Dr. William Davis Parker Jr. M.D. is a Professor of Pediatrics and Head of Division of Pediatric Neurology at the Unversity of Illinois College of Medicine at Peioria, Illinois where he conducts clinical research on schizophrenia, autism and other CNS disorders and scientific research on mitochondrial genomics in Parkinson's, Alzheimer's and other CNS diseases. Dr. Parker is Co-Founder, President and Director of Gene Solutions LLC, a mitochondrial solutions company in Charlottesville, Virginia. He previously held positions as Eugene P. Meyer Professor of Neurology and Pediatrics in the Department of Neurology and Pediatrics & The Center for the Study of Neurodegenerative Disorders, University of Virginia School of Medicine, Charlottesville, Virginia. His research focused on the role of electron transport chain defects in the pathogenesis of Parkinson's disease, Alzheimer's disease and psychiatric disorders. He co-founded Mitokor, a mitochondrial DNA company. He completed a Metabloic Disease Fellowship on Mitochondial Biochemistry at the University of Colorado and was a Muscular Dystrophy Association Research Fellow at the B.F. Stolinski Research Laboratories at the University of Colorado. He was also an Instructor in Neurology and Pediatrics and Associate Professor in Neurology and Pediatrics at the University of Colorado. He received his undergraduate degree from John Hopkins University and his M.D. from University of South Florida and subsequently completed a residency in Neurology at the University of Virginia and did a Fellowship in Clinical Genetics at the University of Virginia.

​

Dr. Jay S. Schneider is Professor of Pathology, Anatomy, Cell Biology and Director of the Parkinson's Research Unit, Thomas Jefferson University, Jefferson Medical College, Philadelphia, Pennsylvania. He formerly held positions as Postdoctoral Fellow at University of California at Los Angeles Neuropsychiatric Institute; Assistant Professor of Neurology at University of California at Los Angeles; Associate Professor of Neurology, Hahnemann University; Professor of Neurobiology and Anatomy at Allegheny University of the Health Sciences, Philadelphia, Pennsylvania. He received a Ph.D. in Physiological Psychology from State University of New York at Stony Brook.

​

L. Blair Shamel is President at The Shamel Group Incorporated and Member of the Board of Directors, Nanospectra Biosciences. He previously held positions as President and CEO, SNP Bio Inc., VP and General Manager, Cancer Diagnostics, Metabolon, VP Corporate Development at DiagnoCure, Inc.; President and CEO at CyMetRx; Director of Product Development at Ablation Technologies; Marketing, Sales, Product Development and Strategic Planning with Hybritech Inc., a subsidiary of Beckman Instruments and prior thereto with Eli Lilly Inc. He has particular expertise in prostate cancer products. He received a B.S. in Biology from Rhodes College and a M.S. in Pharmacology from Emory University.